miR-296在纤维化相关疾病中作用的研究进展

摘要/Abstract

摘要： 纤维化是机体过度的修复反应,可导致多种组织和器官功能障碍,表现为成纤维细胞活化、增殖和细胞外基质过度沉积。微小核糖核酸（microRNA,miRNA）不仅直接参与多器官纤维化进程,表达水平也受纤维化程度影响,是一种关键的调控因子。近年来研究发现,miR-296在纤维化相关疾病中表达失调,通过靶向调控参与TGF-β和JAK2/STAT3等纤维化信号通路、炎症反应、细胞凋亡、自噬、胶原合成和毛细血管损伤的靶基因,影响成纤维细胞的增殖、上皮细胞-间充质转化、细胞外基质的合成与降解,调节纤维化进程。本文综述了miR-296参与纤维化相关疾病的作用机制及其在纤维化相关疾病诊断和治疗方面的潜力。

关键词: miR-296, 纤维化相关疾病, 作用机制, 研究进展

Abstract: The fibrosis is an excessive repair response of the organism,which can lead to a variety of tissue and organ dysfunctions manifested by fibroblast activation,proliferation and excessive deposition of extracellular matrix. The microRNA（miRNA） is not only directly involved in the process of multi-organ fibrosis,but also the expression level is affected by the degree of fibrosis,which is a key regulatory factor. In recent years,miR-296 has been found to be dysregulated in fibrosis-related diseases,targets genes involved in fibrosis signaling pathways such as TGF-β and JAK2/STAT3,inflammatory response,cell apoptosis,autophagy,collagen synthesis,and capillary injury through targeted regulation,fibroblast proliferation,epithelial mesenchymal transition,synthesis and degradation of extracellular matrix,and regulates fibrosis process. The paper reviews the mechanism of miR-296's involvement in fibrosis-associated diseases and its potential in the diagnosis and treatment of fibrosis-associated diseases.

Key words: miR-296, Fibrosis-related diseases, Mechanism of action, Review

中图分类号:

R181.3

王辰宇, 叶丽芳, 刘苏. miR-296在纤维化相关疾病中作用的研究进展. [J]职业与健康, 2025, 41(3): 420-424.

WANG Chenyu, YE Lifang, LIU Su. Advances in role of miR-296 in fibrosis-related diseases. [J]OCCUPATION AND HEALTH, 2025, 41(3): 420-424.

参考文献

[1] 韩敏,聂静,李萃,等.脏器纤维化的研究进展和重要科学问题[J].中国病理生理杂志,2018,34(8):1518-1526.
[2] WYNN T A,RAMALINGAM T R.Mechanisms of fibro-sis:Therapeutic translation for fibrotic disease[J].Nat Med,2012,18(7):1028-1240.
[3] ANDREOU I,SUN X,STONE P H,et al.miRNAs in atherosclerotic plaque initiation,progression,and rupture[J].Trends Mol Med,2015, 21(5):307-318.
[4] BARTEL D P.MicroRNAs:Genomics,biogenesis,mechanism,and function[J].Cell,2004,116(2):281-297.
[5] JIANG X,TSITSIOU E,HERRICK S E,et al.MicroRNAs and the regulation of fibrosis[J].FEBS J,2010,277(9):2015-2021.
[6] SCHNAPER H W,KOPP J B.Renal fibrosis[J].Front Biosci,2003,8:e68-e86.
[7] 叶泽华,夏煜琦,程帆.miRNA和lncRNA在肾纤维化中作用的研究进展[J].中华实用诊断与治疗杂志,2022,36(11):1185-1188.
[8] NI W J,TANG L Q,WEI W.Research progress in signalling pathway in diabetic nephropathy[J].Diabetes Metab Res Rev,2015,31(3):221-233.
[9] ZHANG W,ZHANG S.Downregulation of circRNA-0000285 suppresses cervical cancer development by regulating miR197-3p-ELK1 Axis[J].Cancer Manag Res,2020,12:8663-8674.
[10] XIONG D D,DANG Y W,LIN P,et al.A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma[J].J Transl Med,2018,16(1):220.
[11] TANG B,LI W,JI T T,et al.Circ-AKT3 inhibits theaccumulation of extracellular matrix of mesangial cells in diabetic nephropathy via modulating miR-296-3p/E-cadherin signals[J].J Cell Mol Med,2020, 24(15):8779-8788.
[12] ZEISBERG E M,POTENTA S E,SUGIMOTO H,et al.Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition[J]. J Am Soc Nephrol,2008,19(12):2282-2287.
[13] VILLAREJO A,CORTÉS-CABRERA A,MOLINA-ORTÍZ P,et al. Differential role of Snail1 and Snail2 zinc fingers in E-cadherin repression and epithelial to mesenchymal transition[J].J Biol Chem,2014,289(2):930-941.
[14] WANG Y,LIU Y,ZHANG L,et al.miR-30b-5p modulate renal epithelial-mesenchymal transition in diabeticnephropathy by directly targeting SNAI1[J].Biochem Biophys Res Commun,2021,535:12-18.
[15] 刘苏,徐巍龙,查敏,等.miR-296-5p在糖尿病肾病db/db小鼠血浆外泌体中的表达及功能[J].南京医科大学学报(自然科学版),2022, 42(1):14-22.
[16] CHEN F,XIE Y,LV Q,et al.Curcumin mediates repulsive guidance molecule B(RGMb) in the treatment mechanism of renal fibrosis induced by unilateral ureteral obstruction[J].Ren Fail,2021,43(1):1496-1505.
[17] MAEDA S,MATSUI T,TAKEUCHI M,et al.Sodiumglucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis[J].Diabetes Metab Res Rev,2013,29(5):406-412.
[18] CHEN S.circ_000166/miR-296 Aggravates the process of diabetic renal fibrosis by regulating the SGLT2 signaling pathway in renal tubular epithelial cells[J].Dis Markers,2022,2022:6103086.
[19] KANG D H,ANDERSON S,KIM Y G,et al.Impaired angiogenesis in the aging kidney:Vascular endothelial growth factor and thrombospondin-1 in renal disease[J].Am J Kidney Dis,2001,37(3):601-611.
[20] LI S,WANG F,SUN D.The renal microcirculation in chronic kidney disease:Novel diagnostic methods and therapeutic perspectives[J].Cell Biosci,2021,11(1):90.
[21] CHEVALIER R L,FORBES M S,THORNHILL B A.Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy[J].Kidney Int,2009,75(11):1145-1152.
[22] BORGES F T,MELO S A,ÖZDEMIR B C,et al.TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis[J].J Am Soc Nephrol,2013, 24(3):385-392.
[23] GRANGE C,SKOVRONOVA R,MARABESE F,et al.Stem cell-derived extracellular vesicles and kidney regeneration[J].Cells,2019,8(10):1240.
[24] SAHOO S,KLYCHKO E,THORNE T,et al.Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity[J] Circ Res,2011,109(7):724-728.
[25] CANTALUPPI V,GATTI S,MEDICA D,et al.Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells[J].Kidney Int,2012,82(4):412-427.
[26] KAPITSINOU P P,JAFFE J,MICHAEL M,et al.Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury[J].Am J Physiol Renal Physiol,2012,302(9):1172-1179.
[27] ROEHLEN N,CROUCHET E,BAUMERT T F.Liver fibrosis:Mechanistic concepts and therapeutic perspectives[J].Cells,2020,9(4):875.
[28] HE Y,HUANG C,LIN X,et al.MicroRNA-29 family,a crucial therapeutic target for fibrosis diseases[J].Biochimie,2013,95(7):1355-1359.
[29] HIGASHI T,FRIEDMAN S L,HOSHIDA Y.Hepatic stellate cells as key target in liver fibrosis[J].Adv Drug Deliv Rev,2017:121127-121142.
[30] TSUCHIDA T,FRIEDMAN S L.Mechanisms of hepatic stellate cell activation[J].Nat Rev Gastroenterol Hepatol,2017,14(7):397-411.
[31] EZHILARASAN D.MicroRNA interplay between hepatic stellate cell quiescence and activation[J].Eur J Pharmacol,2020,885:173507.
[32] ZHANGDI H J,SU S B,WANG F,et al.Crosstalk network among multiple inflammatory mediators in liver fibrosis[J].World J Gastroenterol,2019,25(33):4835-4849.
[33] TSAI Y S,YEH M L,TSAI P C,et al.Clusters of Circulating let-7 family tumor suppressors are associated with clinical characteristics of chronic hepatitis C[J].Int J Mol Sci,2020,21(14):4945.
[34] TAVAKOLI DARGANI Z,SINGLA D K.Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis[J].Am J Physiol Heart Circ Physiol,2019,317(2):H460-H471.
[35] 马艳珍. CircAno6/miR-296-3p/TLR4信号轴介导炎症级联反应诱导HSCs活化的机制及疏肝健脾方的干预研究[D].合肥:安徽中医药大学,2023.
[36] LEE S J,KIM K H,PARK K K.Mechanisms of fibrogenesis in liver cirrhosis:The molecular aspects of epithelial-mesenchymal transition[J].World J Hepatol,2014,6(4):207-216.
[37] SHAKERI H,BOEN J R A,DE MOUDT S,et al.Neuregulin-1 compensates for endothelial nitric oxide synthase deficiency[J].Am J Physiol Heart Circ Physiol,2021,320,H2416-H2428.
[38] SHI D M,SHI X L,XING K L,et al.miR-296-5p suppresses stem cell potency of hepatocellular carcinoma cells via regulating Brg1/Sall4 axis[J].Cell Signal,2020,72:109650.
[39] 张靖,左雁,李振宇,等.miRNA调控肺纤维化信号通路TGF-β的研究进展[J].世界最新医学信息文摘,2016,16(A2):32-33,35.
[40] LIU H,CHENG Y,YANG J,et al.BBC3 in macrophages promoted pulmonary fibrosis development through inducing autophagy during silicosis[J].Cell Death Dis,2017,8(3):e2657.
[41] WU Q,JIAO B,ZHANG Q,et al.Identification of circRNA expression profiles and the potential role of hsa_circ_0006916 in silicosis and pulmonary fibrosis[J].Toxicology,2023,483:153384.
[42] SOLIMAN H,ROSSI F M V.Cardiac fibroblast diversity in health and disease[J].Matrix Biol,2020,91-92:75-91.
[43] LIN R,RAHTU-KORPELA L,SZABO Z,et al.MiR-185-5p regulates the development of myocardial fibrosis[J].J Mol Cell Cardiol,2022, 165:130-140.
[44] WEBER K T,SUN Y,BHATTACHARYA S K,et al.Myofibroblast-mediated mechanisms of pathological remodelling of the heart[J].Nat Rev Cardiol,2013,10(1):15-26.
[45] YIN Z,GUO Y,ZHANG J,et al.Association between an indel polymorphism in the 3'UTR of COL1A2 and the risk of sudden cardiac death in Chinese populations[J].Leg Med(Tokyo),2017,28:22-26.
[46] VIENBERG S,GEIGER J,MADSEN S,et al.MicroRNAs in metabo-
lism[J].Acta Physiol(Oxf),2017,219(2):346-361.
[47] FANG L,ELLIMS A H,MOORE X L,et al.Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy[J].J Transl Med,2015,13:314.
[48] ZHANG T,WANG X F,WANG Z C,et al.Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation[J].Biomed Pharmacother,2020,129:110287.
[49] 郭冰玉,林枫,白泽明,等.微小RNA-296在兔增生性瘢痕中的表达及对人成纤维细胞的作用[J].中华烧伤杂志,2021,37(8):725-730.
[50] ZHANG X W,WANG L,DING H.Long noncoding RNA AK089579 inhibits epithelial-to-mesenchymal transition of peritoneal mesothelial cells by competitively binding to microRNA-296-3p via DOK2 in peritonealfibrosis[J].FASEB J,2019,33(4):5112-5125.